ClinicalTrials.Veeva

Find clinical trials for Asthma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Rhinitis
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near Milano, Lombardia, ITA:

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations a...

Enrolling
Asthma
Drug: Benralizumab
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 80 other locations

Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing a...

Enrolling
Asthma
Other: Optimized self-management of asthma
Other: Conventional self-management of asthma
Restech

Pavia, Italy and 8 other locations

to budesonide in children from 6 to less than 12 years of age with asthma.The study duration will be up to 37 weeks including an investigati...

Enrolling
Asthma
Drug: Budesonide
Drug: QMF149

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 45 other locations

This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Lombardia, Italy and 141 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Placebo
Drug: Atuliflapon

Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 350 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Enrolling
Asthma
Biological: Placebo
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Lombardia, Italy and 429 other locations

the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Enrolling
Asthma
Drug: BD MDI 320 μg
Drug: Open-label Symbicort TBH 320/9 μg

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 180 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 477 other locations

profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studi...

Enrolling
Asthma
Biological: GSK3511294 (Depemokimab)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Rozzano (MI), Lombardia, Italy and 128 other locations

(MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma...

Not yet enrolling
Asthma
Drug: Salbutamol HFA-152a
Drug: Salbutamol HFA-134a

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Lombardia, Italy and 83 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems